Activity of the MEK inhibitor trametinib in a patient with a BRAF mutation persisting from T-lymphoblastic lymphoma through lineage switch to CNS acute myeloid leukemia

Affiliations

• ¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
• ² Department of Radiology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
• ³ Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
• ⁴ Division of Haematopathology, European Institute of Oncology IRCCS, Milan, Italy.
• ⁵ Hematopathology division, IRCCS Istituto Europeo di Oncologia, Milan, Italy.